Des-γ-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: Association with survival of patients with resectable hepatocellular carcinoma

Oncology Reports

Volumn 13, Issue 1, 2005, Pages 25-30

  Tang, Wei ^a   Kokudo, Norihiko ^a   Sugawara, Yasuhiko ^a   Guo, Qian ^a   Imamura, Hiroshi ^a   Sano, Keiji ^a   Karako, Hirona ^a   Qu, Xianjun ^b,c   Nakata, Munehiro ^b   Makuuchi, Masatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Des carboxyprothrombin; Hepatocellular carcinoma; PIVKA II; Prognosis

Indexed keywords

BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMISTRY; FEMALE; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 21644438232     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.1.25     Document Type: Article

References (30)

1. Okuda K: Epidemiology. In: Diagnosis and Treatment of Hepatocellular Carcinoma. Livraghi T, Makuuchi M and Buscarini L (eds). Greenwich Medical Media, London, pp3-15, 1997.
2. Law MG, Roberts SK, Dore GJ and Kaldor JM: Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust 173: 403-405, 2000.
3. Stroffolini T, Andreone P. Andriulli A, Ascione A, Craxi A, Chiaramonte M, Galante D, Manghisi OG, Mazzanti R, Medaglia C, Pilleri G, Rapaccini GL, Simonetti RG, Taliani G, Tosti ME, Villa E and Gasbarrini G: Characteristics of hepatocellular carcinoma in Italy. J Hepatol 29: 944-952, 1998. (Pubitemid 28559064)
4. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999. (Pubitemid 29114292)
5. Kaczynski J and Oden A: The rising incidence of hepatocellular carcinoma. N Engl J Med 341: 451, 1999.
6. Benhamiche AM, Faivre C, Minello A, Clinard F, Mitry E, Hillon P and Faivre J: Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J Hepatol 29: 802-806, 1998. (Pubitemid 28505938)
7. Furie B and Furie BC: Molecular basis of vitamin K-dependent γ-carboxylation. Blood 75: 1753-1762, 1990. (Pubitemid 20161485)
8. Vermeer C: γ-Caiboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J 266: 625-636, 1990.
9. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS and Furie B: Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Eng J Med 310: 1427-1431, 1984. (Pubitemid 14101298)
10. Weitz IC and Liebman HA: Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 18: 990-997, 1993.
11. Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K and Azuma M: Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Hepatogastroenterology 46: 2464-2468, 1999. (Pubitemid 29454123)
12. Nakagawa T, Seki T, Shiro T, Wakabayashi M, Imamura M, Itoh T, Tamai T, Nishimura A, Yamashiki M, Matsuzaki K, Sakaida N, Inoue K and Okamura A: Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol 14: 281-286, 1999.
13. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M and Nakano M: Serum levels of des-γ-carboxyprothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 88: 544-549, 2000. (Pubitemid 30056927)
14. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A and Maeda T: Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 73: 2464-2471,1994. (Pubitemid 24155520)
15. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S and Omata M: Des-γ-carboxy-prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91: 561-569, 2001. (Pubitemid 32105702)
16. Sakon M, Monden M, Gotoh M, Kanai T, Umeshita K, Nakano Y, Mori T, Sakurai M and Wakasa K: Relationship between pathologic prognostic factors and abnormal levels of des-γ-carboxyprothrombin and alpha-fetoprotein in hepatocellular carcinoma. Am J Surg 163: 251-256, 1992. (Pubitemid 23059267)
17. Inoue S, Nakao A, Harada A, Nonami T and Takagi H: Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 89: 2222-2226, 1994. (Pubitemid 24363674)
18. Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan L-W, Ohnishi S and Makuuchi M: Des-γ-carboxyprothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 22: 969-975, 2003.
19. Yuan L-W, Tang W, Kokudo N, Sugawara Y, Karako H, Hasegawa K, Aoki T, Kyoden Y, Deli G, Li Y-G and Makuuchi M: Measurement of des-gamma- carboxyprothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma. Oncol Rep 12: 269-273, 2004.
20. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd edition. Liver Cancer Study Group of Japan, Tokyo, 2003.
21. Sobin LH and Wittekind C: TNM Classification of Malignant Tumors. 5th edition. Wiley-Liss, New York, 1997.
22. Shi SR, Key ME and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
23. Tang W, Mafune K, Nakata M, Konishi T, Kojima N, Mizuochi T and Makuuchi M: Association of histochemical expression of Maackia amurensis leukoagglutinin-positive glycoconjugates with behaviour of human gastric cancer. Histopathology 42: 239-245,2003. (Pubitemid 36356856)
24. Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, Itano S, Ono N, Yutani S, Nagamatsu H, Matsugaki S, Yamasaki S, Tanikawa K and Sata M: A simultaneous monitoring of Lens culinaris agglutinin A-reactive α-fetoprotein and des-γ-carboxyprothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 7: 249-256, 2000.
25. Miskad UA, Yano Y, Nakaji M, Kishi S, Itoh H, Kim SR, Ku Y, Kuroda Y and Hayashi Y: Histological study of PIVKA-II expression in hepatocellular carcinoma and adenomatous hyperplasia. Pathol Int 51: 916-922, 2001. (Pubitemid 34175518)
26. Ajisaka H, Shimizu K and Miwa K: Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma. J Surg Oncol 84: 89-93, 2003. (Pubitemid 37247914)
27. Suttie JW: Vitamin K-dependent carboxylase. Ann Rev Biochem 54: 459-477, 1985.
28. Miyakawa T, Kajiwara Y, Shirahata A, Okamoto K, Itoh H and Ohsato K: Vitamin K contents in liver tissue of hepatocellular carcinoma patients. Jpn J Cancer Res 91: 68-74, 2000. (Pubitemid 30128939)
29. Huisse MG, Leclercq M, Belghiti J, Flejou JF, Suttie JW, Bezeaud A, Stafford DW and Guillin MC: Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas. Cancer 74: 1533-1541, 1994. (Pubitemid 24302971)
30. Ohta H, Ono M, Ohhira M, Sekiya C and Namiki M: Measurement of tissue vitamin K levels after daily intravenous administration of vitamin K in two patients with hepatocellular carcinoma: biochemical consideration of the mechanism of elevated PIVKA-II production. Acta Hepatol Jpn 31: 790-795, 1990. (Pubitemid 20303824)